Analysis of cancer relapse mechanisms by proteomic profiling using drug-tolerant cell subpopulation
| Project/Area Number |
25830121
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
KUME Kohei 岩手医科大学, 医学部, ポストドクター (10609663)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 抗癌剤耐性 / 癌性腹膜炎 / RNAポリメラーゼ / 逆相タンパク質マイクロアレイ / RNAポリメラーゼII / TAF15 / 薬剤寛容性細胞集団 / コロニー形成 / シスプラチン |
|---|
| Outline of Final Research Achievements |
Cancer relapse is often seen even after curative operation followed by adjuvant chemotherapy. In this study, we analyzed cancer cell colonies that emerge in the presence of anticancer drugs (drug-tolerant colonies, DTCs) as a cancer relapse model. Proteomic characterization of DTCs identified two major subgroups, but none of these characters associated with DTCs. A lead compound screening identified an RNA polymerase inhibitor (RNAPi) bearing potency in DTC suppression. RNAPi with cisplatin significantly reduced the number of nodules of peritoneal dissemination of gastric cancer in mice. These findings suggest that RNAPi is potent in suppression of cancer relapse such as peritoneal dissemination of gastric cancer.
|
Report
(3 results)
Research Products
(13 results)
